These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31517711)

  • 41. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hemostatic management of hemophilia].
    Tokugawa T
    Rinsho Ketsueki; 2022; 63(9):1212-1222. PubMed ID: 36198547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Congenital hemophilia: a new treatment paradigm].
    Shima M
    Rinsho Ketsueki; 2019; 60(6):647-658. PubMed ID: 31281158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
    Monahan PE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 49. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
    Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemophiliacs with inhibitors: therapeutic options.
    Roberts HR
    N Engl J Med; 1981 Sep; 305(13):757-8. PubMed ID: 6790992
    [No Abstract]   [Full Text] [Related]  

  • 51. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Lenting PJ; Denis CV; Christophe OD
    Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.
    Barthels M
    Thromb Res; 1999 Aug; 95(4 Suppl 1):S31-8. PubMed ID: 10499907
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors.
    Teitel JM
    Transfus Apher Sci; 2018 Aug; 57(4):466-471. PubMed ID: 30093246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A.
    Lippi G; Favaloro EJ
    Adv Clin Chem; 2019; 88():151-167. PubMed ID: 30612605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risks and patient outcomes of surgical intervention for hemophilic arthropathy.
    Rodriguez-Merchan EC
    Expert Rev Hematol; 2019 May; 12(5):325-333. PubMed ID: 30929534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hemophilia management in transfusion medicine.
    Poon MC; Card R
    Transfus Apher Sci; 2012 Jun; 46(3):299-307. PubMed ID: 22503305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of hemophilia patients with inhibitors.
    Hedner U; Glazer S
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile.
    Abarca-Villaseca V; Soto-Arellano V
    Am J Case Rep; 2021 Apr; 22():e929598. PubMed ID: 33883542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.